Services.
Fred draws from his two decades of industry experience to help biotechnology companies advance their strategic thinking and pursue partnership opportunities to maximize the impact of their discoveries on human health.
Business Development.
-
Out-Licensing.
End-to-end support for the out-licensing process of pre-clinical and clinical-stage assets including developing confidential presentations, building data rooms, identifying potential parties, collaborating with counsels, managing Q&As, collecting and evaluating term-sheets, and negotiating agreements.
-
In-Licensing.
Identification of in-licensing opportunities that strategically complement the clinical pipeline and commercial portfolio including end-to-end support of the evaluation, due diligence of the asset, valuation, term-sheet development, and contract negotiation.
-
Platform Collaborations.
Development of partnering strategies for platform technologies including prioritization of disease areas and medical conditions of highest potential, identification of potential collaboration partners, development of pitch decks, partnership structures, and data rooms, and negotiation of term-sheets.
Strategy.
-
Portfolio Prioritization.
Prioritization of pre-clinical and clinical assets through the rigorous evaluation of scientific, clinical, technical, manufacturing, regulatory, and commercial considerations, and the development of prioritization frameworks and quantitative analyses to inform recommendations.
-
Long-Range Planning.
Development of multi-year strategic and long-range plans, identification and analysis of key strategic considerations and options; Development of divisional strategic plans (research, commercial, manufacturing, etc.) to achieve corporate goals while optimizing resource allocations.
-
Strategic Transformation.
Analysis of strategic transformations, including M&As, and Divestitures; Development of pro-forma debt and equity financing and return analysis, management presentations, data room creation, Q&A coordination, and deal terms negotiation; Integration/Separation planning and execution.
Valuation.
Asset.
Portfolio.
Company.
Platform.
Valuation of assets and of their optionality, portfolio valuation, technology platform valuation, and wholeco valuation using discounted cash flow (DCF), sum-of-the-parts (SOTP), and comps analysis.